AU2021296151A1 - Methods for treating cancer or von-Hippel Lindau disease using a combination of a HIF-2 alpha inhibitor and lenvatinib - Google Patents
Methods for treating cancer or von-Hippel Lindau disease using a combination of a HIF-2 alpha inhibitor and lenvatinib Download PDFInfo
- Publication number
- AU2021296151A1 AU2021296151A1 AU2021296151A AU2021296151A AU2021296151A1 AU 2021296151 A1 AU2021296151 A1 AU 2021296151A1 AU 2021296151 A AU2021296151 A AU 2021296151A AU 2021296151 A AU2021296151 A AU 2021296151A AU 2021296151 A1 AU2021296151 A1 AU 2021296151A1
- Authority
- AU
- Australia
- Prior art keywords
- rcc
- cancer
- lenvatinib
- hif
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063042307P | 2020-06-22 | 2020-06-22 | |
| US63/042,307 | 2020-06-22 | ||
| US202163146915P | 2021-02-08 | 2021-02-08 | |
| US63/146,915 | 2021-02-08 | ||
| PCT/US2021/038172 WO2021262563A1 (en) | 2020-06-22 | 2021-06-21 | Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021296151A1 true AU2021296151A1 (en) | 2023-02-02 |
Family
ID=79281740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021296151A Pending AU2021296151A1 (en) | 2020-06-22 | 2021-06-21 | Methods for treating cancer or von-Hippel Lindau disease using a combination of a HIF-2 alpha inhibitor and lenvatinib |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230210838A1 (https=) |
| EP (1) | EP4168008B1 (https=) |
| JP (1) | JP7750884B2 (https=) |
| KR (1) | KR20230026493A (https=) |
| CN (1) | CN115803629A (https=) |
| AU (1) | AU2021296151A1 (https=) |
| BR (1) | BR112022026094A2 (https=) |
| CA (1) | CA3183852A1 (https=) |
| MX (2) | MX2022016406A (https=) |
| WO (1) | WO2021262563A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115463217B (zh) * | 2021-06-11 | 2024-03-12 | 深圳埃格林医药有限公司 | 己酸羟孕酮在增强肿瘤治疗效果中的应用 |
| CN119731864A (zh) | 2023-02-28 | 2025-03-28 | 株式会社Lg新能源 | 电化学装置用分隔件和包括其的电化学装置 |
| AU2024248799A1 (en) * | 2023-03-31 | 2025-10-23 | Daiichi Sankyo Company, Limited | Combination of anti-CDH6 antibody-drug conjugate and HIF-2alpha inhibitor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016168510A1 (en) * | 2015-04-17 | 2016-10-20 | Peloton Therapeutics, Inc. | Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
| WO2018031680A1 (en) * | 2016-08-10 | 2018-02-15 | Fronthera U.S. Pharmaceuticals Llc | Novel compounds, uses and methods for their preparation |
| WO2020081695A1 (en) * | 2018-10-17 | 2020-04-23 | Nikang Therapeutics, Inc. | Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors |
-
2021
- 2021-06-21 JP JP2022578935A patent/JP7750884B2/ja active Active
- 2021-06-21 CN CN202180049537.5A patent/CN115803629A/zh active Pending
- 2021-06-21 KR KR1020237002565A patent/KR20230026493A/ko active Pending
- 2021-06-21 AU AU2021296151A patent/AU2021296151A1/en active Pending
- 2021-06-21 CA CA3183852A patent/CA3183852A1/en active Pending
- 2021-06-21 EP EP21828761.3A patent/EP4168008B1/en active Active
- 2021-06-21 BR BR112022026094A patent/BR112022026094A2/pt unknown
- 2021-06-21 MX MX2022016406A patent/MX2022016406A/es unknown
- 2021-06-21 US US18/009,115 patent/US20230210838A1/en active Pending
- 2021-06-21 WO PCT/US2021/038172 patent/WO2021262563A1/en not_active Ceased
-
2022
- 2022-12-16 MX MX2025014865A patent/MX2025014865A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4168008A1 (en) | 2023-04-26 |
| JP7750884B2 (ja) | 2025-10-07 |
| JP2023531675A (ja) | 2023-07-25 |
| MX2025014865A (es) | 2026-01-07 |
| US20230210838A1 (en) | 2023-07-06 |
| EP4168008B1 (en) | 2026-03-18 |
| MX2022016406A (es) | 2023-01-30 |
| CN115803629A (zh) | 2023-03-14 |
| CA3183852A1 (en) | 2021-12-30 |
| EP4168008A4 (en) | 2024-08-07 |
| WO2021262563A1 (en) | 2021-12-30 |
| BR112022026094A2 (pt) | 2023-01-17 |
| KR20230026493A (ko) | 2023-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reardon et al. | Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges | |
| Bendell et al. | A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors | |
| EP4168008B1 (en) | A combination of belzutifan and lenvatinib for use in treating cancer | |
| US20230181565A1 (en) | Crenolanib combination therapy | |
| EP3721906A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| Scaringi et al. | Combining molecular targeted agents with radiation therapy for malignant gliomas | |
| WO2018170457A1 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
| WO2023100070A1 (en) | Cdk4 inhibitor for the treatment of cancer | |
| TWI771344B (zh) | 一種ｖｅｇｆｒ抑制劑與ｐａｒｐ抑制劑聯合在製備治療胃癌的藥物中的用途 | |
| JP2023531683A5 (https=) | ||
| EP4168016A2 (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof | |
| WO2021262562A2 (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof | |
| RU2858600C2 (ru) | Способы лечения рака или болезни фон-гиппеля-линдау с использованием комбинации ингибитора hif-2 альфа и ленватиниба или его фармацевтически приемлемой соли | |
| JP7308145B2 (ja) | 固形腫瘍を治療するための医薬組成物 | |
| Carrato et al. | Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer | |
| HK40087480A (zh) | 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法 | |
| US20210113692A1 (en) | Dosing regimen | |
| RU2777519C2 (ru) | Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы | |
| Wagner | Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugs | |
| Theodore et al. | Topoisomerase Therapy in | |
| WO2024231875A1 (en) | Hpk1 inhibitor for use in the treatment of cancer | |
| JP2024531653A (ja) | 固形腫瘍の処置のための経口投与パクリタキセル、Ｐ－ｇｐ阻害剤、およびチェックポイント阻害剤の治療的組み合わせ | |
| WO2026037393A1 (zh) | 一种抗体药物偶联物与酪氨酸激酶抑制剂的组合 | |
| Chen et al. | Preclinical activity of the rational combination of apatinib in combination with CPT-11 in KRAS-mutant colorectal cancer patient-derived xenograft model | |
| Wu et al. | Molecularly targeted therapy for metastatic colon cancer: Proven treatments and promising new agents |